(57 days)
Not Found
Not Found
No
The summary describes a standard immunoassay analyzer and does not mention any AI or ML capabilities, image processing, or data training/testing sets typically associated with AI/ML devices.
No
The Elecsys 2010 analyzer is used for in vitro diagnostic analysis of analytes in body fluids, not for treating a disease or condition.
Yes
The device is intended for "quantitative and qualitative analysis of analytes in body fluids" and "qualitative determination of analytes in human serum and plasma," which are activities performed to diagnose diseases or conditions.
No
The device description explicitly states it is a "fully automated, random access, computer controlled analytical system," indicating it includes hardware components beyond just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The description explicitly states the device is intended for "in vitro quantitative and qualitative analysis of analytes in body fluids" and "in vitro... qualitative determination of analytes in human serum and plasma." The term "in vitro" is the defining characteristic of an IVD.
- Device Description: The description reinforces this by stating it's an "analytical system for quantitative and qualitative determinations of analytes in body fluids."
The core function of the device is to analyze substances (analytes) in samples taken from the body (body fluids, serum, plasma) outside of the body ("in vitro"). This directly aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Elecsys 2010 analyzer is intended to be used for the in vitro quantitative and qualitative analysis of analytes in body fluids.
The Elecsys 2010 analyzer is an immunoassay analyzer intended for the in vitro. The formation of qualitative determination of analytes in human serum and plasm The Elecsys 2010 analyzer is an immunoassay analyzer intended for the II. The II. The Street.
Product codes (comma separated list FDA assigned to the subject device)
CDX, CEC, DHA, JJE, JLW, KHQ, MMI
Device Description
The Elecsys 2010 analyzer is a fully automated, random access, computer controlled analytical system for quantitative and qualitative determinations of analytes in body fluids.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Method Comparison T4: Y = 1.02x +0.85, SEE = 5.39, r = 0.947
Method Comparison FT4: Y = 0.954X + 0.18, SEE = 1.11, r = 0.981
Method Comparison TSH: Y = 1.09X + 0.14, SEE = 0.798, r = 0.991; n = 132
Method Comparison T-Uptake: Y = 0.99X - 0.03, SEE = 0.04, r = 0.908; n = 319
Method Comparison hCG: Y = 1.35X - 9.21, SEE = 17.50, r = 0.989; n = 64
Method Comparison Troponin-T: Y = - 0.033 + 0.996, SEE = 0.547, r = 0.969; n = 54
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.2160 Discrete photometric chemistry analyzer for clinical use.
(a)
Identification. A discrete photometric chemistry analyzer for clinical use is a device intended to duplicate manual analytical procedures by performing automatically various steps such as pipetting, preparing filtrates, heating, and measuring color intensity. This device is intended for use in conjunction with certain materials to measure a variety of analytes. Different models of the device incorporate various instrumentation such as micro analysis apparatus, double beam, single, or dual channel photometers, and bichromatic 2-wavelength photometers. Some models of the device may include reagent-containing components that may also serve as reaction units.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
JUN 1 4 1996
ਸਿੰਘ ਸੀ।
ਹਵਾਲੇ
510(k) Summary
| Introduction | According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence. |
|---|---|
| 1) Submitter name, address, contact | Boehringer Mannheim Corporation |
| 9115 Hague Rd. | |
| Indianapolis, IN 46250 | |
| (317) 845-2327 | |
| Contact Person: John D. Stevens | |
| Date Prepared: April 17, 1996 | |
| 2) Device name | Proprietary name: Elecsys 2010 ® analyzer |
| Common name: immunoassay analyzer | |
| Classification name: Discrete photometric analyzer for clinical use | |
| 3) Predicate device | We claim substantial equivalence to the Boehringer Mannheim ES300 Immunoassay system. |
| 4) Device Description | The Elecsys 2010 analyzer is a fully automated, random access, computer controlled analytical system for quantitative and qualitative determinations of analytes in body fluids |
| 5) Intended use | The Elecsys 2010 analyzer is intended to be used for the in vitro quantitative and qualitative analysis of analytes in body fluids. |
| Continued on next page |
1
510(k) Summary Elecsys® 2010 Analyzer, Continued
- Comparison to predicate 'device
The Boehringer Mannheim Elecsys 2010 analyzer is substantially equivalent to other products in commercial distribution intended for similar use. Most notably it is substantially equivalent to the currently marketed ES300 Immunoassay analyzer.
The following table compares the Elecsys 2010 with the predicate device. Specific data on the performance of the system have been incorporated into the draft labeling in attachment 5. Labeling for the predicate device in provided in attachment 6.
Similarities:
| Feature | Elecsys 2010 Analyzer | ES300 Analyzer |
|---|---|---|
| Intended use | Intended for the in vitro | |
| quantitative/qualitative | ||
| determination of analytes in | ||
| body fluids | Same | |
| Number of | ||
| reagents | Up to 2 | Same |
| Sample | ||
| detection | Liquid level detection and | |
| clot detection | Same | |
| Sample type | Serum and plasma | Same |
| Host interface | RS232C bidirectional | Same |
Differences:
| Feature | Elecsys 2010 analyzer | ES300 analyzer |
|---|---|---|
| Operating | ||
| principle | Electrochemiluminescence | |
| immunoassay method type | Enzyme-linked | |
| immunosorbent assay method | ||
| type | ||
| Detection | ||
| system | Flow through | |
| electrochemiluminescence | ||
| detection cell | Flow through cuvette with | |
| halogen lamp light source | ||
| Sample | ||
| positions | 30 positions for samples, | |
| controls and calibrators | 150 positions for samples, | |
| controls and calibrators | ||
| Sample | ||
| volume / test | 10 to 50μL | 5 to 200 μL |
| Reagent | ||
| positions | 15 reagent positions | |
| 2 diluent/reagent positions | ||
| 1 BlankCell position | 12 reagent positions | |
| 1 cleaning solution | ||
| 2 universal substrate |
Continued on next page
2
510(k) Summary, Elecsys 2010® Analyzer Continued
- Comparison to predicate device, (cont.)
ان کے شہر
حوالہ جات
Performance Characteristics:
| Feature | Elecsys 2010 vs. ES300
Least Squares Regression |
|------------------------------------|---------------------------------------------------------------|
| Method
Comparison
T4 | $Y = 1.02x +0.85$
$SEE = 5.39$
$r = 0.947$ |
| Method
Comparison
FT4 | $Y = 0.954X + 0.18$
$SEE = 1.11$
$r = 0.981$ |
| Method
Comparison
TSH | $Y = 1.09X + 0.14$
$SEE = 0.798$
$r = 0.991; n = 132$ |
| Method
Comparison
T-Uptake | $Y = 0.99X - 0.03$
$SEE = 0.04$
$r = 0.908; n = 319$ |
| Method
Comparison
hCG | $Y = 1.35X - 9.21$
$SEE = 17.50$
$r = 0.989; n = 64$ |
| Method
Comparison
Troponin-T | $Y = - 0.033 + 0.996$
$SEE = 0.547$
$r = 0.969; n = 54$ |
3
Image /page/3/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES" in a bold, sans-serif font. The text is arranged on a single line and is centrally aligned. The words are capitalized and evenly spaced.
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized representation of an eagle or bird with three curved lines forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the bird symbol.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 1 7 2000
Ms. Kay Taylor Regulatory Affairs, Laboratory Systems Roche Diagnostics Corporation 9115 Hague Road P.O. Box 50457 Indianapolis, Indiana 46250-0457
Re: K961481 Trade Name: Elecsys 2010 Analyzer Regulatory Class: II Product Code: CDX, CEC, DHA, JJE, JLW, KHQ, MMI Dated: May 29, 1996 Received: May 30, 1996
Dear Ms. Taylor:
This letter corrects our substantially equivalent letter of June 14, 1996, regarding the Elecsys 2010 Analyzer. The Elecsys 2010, associated reagents, and subsequent models within the Elecsys Family of analyzers referenced in K961481 were only classified as a class I device. Elecsys analyzers with their associated reagents are considered combination devices and carry the highest classification as stated in Blue Book memo #K86-3 "When such a device is found to be SE, it combines devices from different classes and is classified in the highest of the predicate device classifications."
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use ato t and re enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that prior to they 20, 1978, and in the provisions of the Federal Food, Drug, and Cosmetic Act (Act (Act). You may, therefore, market the device, subject to the general controls Cosmone Act. The Act. The general controls provisions of the Act include requirements for annual provision, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III If your device is elassifited to such additional controls. Existing major regulations (1 centurior reproval) in the Code of Federal Regulations, Title 21, Parts 800 to 895.
4
A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed noulicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, (302) 59 mtet the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Kim Zofia
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known): V961481
Device Name: Elecsys® 2010 Analyzer
Indications for Use:
ﻧﮯ ﺗ
11
ﺗ
The Elecsys 2010 analyzer is an immunoassay analyzer intended for the in vitro.
The formation of qualitative determination of analytes in human serum and plasm The Elecsys 2010 analyzer is an immunoassay analyzer intended for the II. The II. The Street
C. Robhs
(Division Sign-Off) Division of Clinical Laboratory I 510(k) Number.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109) OR
Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)